Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MARSAM AND GENEVA GENERICS ENTER JOINT OPERATING ARRANGEMENT

Executive Summary

MARSAM AND GENEVA GENERICS ENTER JOINT OPERATING ARRANGEMENT under an agreement in principle announced April 16. Upon the signing of a definitive 10-year agreement, Marsam Pharmaceuticals will develop and produce generic injectable products, while Ciba-Geigy subsidiary Geneva will focus on unit-dose solid generic drugs. Coopers & Lybrand was financial advisor for Marsam's proposed deal with Ciba-Geigy. Marsam would not predict when a definitive agreement would be reached. Products developed by both companies will be marketed by Geneva under the Geneva-Marsam brandname with profits shared by both firms. Geneva's current sales force stands at approximately 65. The company plans to create a hospital/institutional sales force initially numbering 18 and expected to grow to about 40 over the next several years. Ciba-Geigy entered the U.S. generic market in mid-1979 with the $8.5 mil. cash acquisition of S.J. Tutag (renamed Geneva Generics), which is based in Broomfield, Colorado. The Tutag deal offered Ciba-Geigy an established generic line. Marsam only began marketing products in January 1989, but the firm had about 29 ANDAs pending as of last September, along with about 18 products in development. As part of the arrangement, Ciba-Geigy will pay $10 mil. for a 10% equity position in Marsam. The Summit, N.J.-based generic manufacturer has nearly 5 mil. shares of common stock outstanding. Prior to the announcement, Marsam was trading on the NASDAQ at around 21. The stock closed Friday, April 20 at 19-3/4. The agreement with Geneva Generics will replace one signed in 1985 with Squibb before that company's July 1989 merger with Bristol-Myers. Covering injectable generic drugs, the Squibb agreement was slated to expire at the end of 1991. Some final details on dissolution of the agreement are still pending. Squibb currently holds an 8.1% equity stake in Marsam via warrants to purchase up to 350,000 shares of Marsam. Those warrants are exercisable until Jan. 31, 1991. In September 1989, Marsam said it was in preliminary discussions with other companies about developing a joint operating arrangement similar to the Squibb Mark-Marsam deal. Besides Squibb, Marsam's other major corporate holder is Agvar Chemicals, which controlled more than 10% of the company (as of July 5) with ownership of 740,474 shares of common. That same month, Marsam moved to increase its independence from the newly created Bristol-Myers Squibb when it earmarked $7-$10 mil. from $14.3 mil. raised in a public stock offering to build a new production facility and develop non-penicillin, non-cephalosporin products ("The Pink Sheet" Sept. 18, T&G-3). The plant is expected to be up and running fully by 1992, Marsam forecasts. At the time of the stock offering, all but one of the non-penicillin, non-cephalosporin products marketed by Marsam were being manufactured by Squibb. Today, Marsam markets 17 products, 11 of which are being manufactured by Squibb and six by Marsam. Marsam reported 1989 revenues of nearly $6 mil. and a net loss of $503,900.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel